These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 10770537)

  • 21. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
    AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.
    Duong M; Piroth L; Grappin M; Forte F; Peytavin G; Buisson M; Chavanet P; Portier H
    HIV Clin Trials; 2001; 2(2):128-35. PubMed ID: 11590521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Baxter JD; Mayers DL; Wentworth DN; Neaton JD; Hoover ML; Winters MA; Mannheimer SB; Thompson MA; Abrams DI; Brizz BJ; Ioannidis JP; Merigan TC
    AIDS; 2000 Jun; 14(9):F83-93. PubMed ID: 10894268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
    Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
    AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.
    Gianotti N; Seminari E; Lazzarin A; Boeri E; Clementi M; Danise A; Salpietro S; Fusetti G; Castagna A
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):545-54. PubMed ID: 15989459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
    Bangsberg DR; Charlebois ED; Grant RM; Holodniy M; Deeks SG; Perry S; Conroy KN; Clark R; Guzman D; Zolopa A; Moss A
    AIDS; 2003 Sep; 17(13):1925-32. PubMed ID: 12960825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.
    Gardner EM; Sharma S; Peng G; Hullsiek KH; Burman WJ; Macarthur RD; Chesney M; Telzak EE; Friedland G; Mannheimer SB
    AIDS; 2008 Jan; 22(1):75-82. PubMed ID: 18090394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
    Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 35. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
    Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
    Gibb DM; Goodall RL; Giacomet V; McGee L; Compagnucci A; Lyall H;
    Pediatr Infect Dis J; 2003 Jan; 22(1):56-62. PubMed ID: 12544410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.